KR20210144767A - 암 치료용 의약 - Google Patents

암 치료용 의약 Download PDF

Info

Publication number
KR20210144767A
KR20210144767A KR1020217033277A KR20217033277A KR20210144767A KR 20210144767 A KR20210144767 A KR 20210144767A KR 1020217033277 A KR1020217033277 A KR 1020217033277A KR 20217033277 A KR20217033277 A KR 20217033277A KR 20210144767 A KR20210144767 A KR 20210144767A
Authority
KR
South Korea
Prior art keywords
antibody
ser
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217033277A
Other languages
English (en)
Korean (ko)
Inventor
고지 나카무라
고타 다카하시
이즈미 사카구치
링이 장
Original Assignee
치오메 바이오사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치오메 바이오사이언스 가부시키가이샤 filed Critical 치오메 바이오사이언스 가부시키가이샤
Publication of KR20210144767A publication Critical patent/KR20210144767A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020217033277A 2019-04-01 2020-03-31 암 치료용 의약 Pending KR20210144767A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019070120 2019-04-01
JPJP-P-2019-070120 2019-04-01
PCT/JP2020/014832 WO2020204033A1 (ja) 2019-04-01 2020-03-31 がん治療用医薬

Publications (1)

Publication Number Publication Date
KR20210144767A true KR20210144767A (ko) 2021-11-30

Family

ID=72668636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033277A Pending KR20210144767A (ko) 2019-04-01 2020-03-31 암 치료용 의약

Country Status (10)

Country Link
US (1) US20220193064A1 (https=)
EP (1) EP3949990A4 (https=)
JP (1) JP7549889B2 (https=)
KR (1) KR20210144767A (https=)
CN (1) CN113660954B (https=)
AU (1) AU2020255907A1 (https=)
CA (1) CA3135157A1 (https=)
IL (1) IL286680A (https=)
TW (1) TWI862564B (https=)
WO (1) WO2020204033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4226945A4 (en) * 2020-10-05 2024-10-23 Chiome Bioscience, Inc MEDICINES FOR THE TREATMENT OF CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
CN1304046C (zh) * 2004-06-29 2007-03-14 上海人类基因组研究中心 肝癌相关基因dlk1及其应用
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR102091871B1 (ko) 2012-07-26 2020-03-20 덴카 주식회사 수지 조성물
ES2665341T3 (es) * 2012-10-03 2018-04-25 Chiome Bioscience Inc. Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo
SI3579883T1 (sl) * 2017-02-08 2021-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kudo M, et al., Lancet, vol. 391 (10126), p. 1163-1173, 2018

Also Published As

Publication number Publication date
CA3135157A1 (en) 2020-10-08
EP3949990A1 (en) 2022-02-09
CN113660954B (zh) 2025-01-14
IL286680A (en) 2021-10-31
AU2020255907A1 (en) 2021-10-28
CN113660954A (zh) 2021-11-16
US20220193064A1 (en) 2022-06-23
JP7549889B2 (ja) 2024-09-12
JPWO2020204033A1 (https=) 2020-10-08
WO2020204033A1 (ja) 2020-10-08
TW202104259A (zh) 2021-02-01
EP3949990A4 (en) 2023-02-08
TWI862564B (zh) 2024-11-21

Similar Documents

Publication Publication Date Title
ES2427964T3 (es) Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
AU2025203336A9 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
US7241444B2 (en) Anti-IGF-IR antibodies and uses thereof
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
KR20120060235A (ko) 특이성 결합 단백질 및 용도
KR102904453B1 (ko) 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트
JP2021524251A (ja) Ｃｄ３に特異的な抗体及びその使用
JP7469305B2 (ja) 抗ｐｄ－１抗体およびその使用
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
KR20180117067A (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
JP2019502670A (ja) 癌の治療のための新規抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
US12534541B2 (en) Anti-PTK7 antibody and uses thereof
JP2023506805A (ja) 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
KR20210144767A (ko) 암 치료용 의약
KR20230083296A (ko) 암 치료용 의약
CN102282172B (zh) 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
TW202146458A (zh) 一種抗PD-L1/TGF-β融合蛋白
WO2026052782A1 (en) Anti-globo h antibodies
HK40115552A (zh) 抗ptk7抗体及其用途
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK1078590B (en) Novel anti-igf-ir antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000